You're viewing our updated article page. If you need more time to adjust, you can return to the old layout.

CORRECTION article

Front. Pharmacol., 13 November 2025

Sec. Drugs Outcomes Research and Policies

Volume 16 - 2025 | https://doi.org/10.3389/fphar.2025.1735585

Correction: Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma

  • 1. Department of Pharmacy, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China

  • 2. Department of Pharmacy, Zunyi Bozhou District People’s Hospital, Zunyi, Guizhou, China

  • 3. Sinopharm Group Tongjitang (Guizhou) Pharmaceutical Co., Ltd., Economic and Technological Development District, Guiyang, Guizhou, China

  • 4. Guangxi Shenli Pharmaceutical Co., Ltd., Yulin, Guangxi, China

  • 5. School of Nursing, Zunyi Medical University, Zunyi, Guizhou, China

Article metrics

View details

604

Views

48

Downloads

Affiliation 1 Department of Pharmacy, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China was omitted for author Tong-Xia Xia. This affiliation has now been added for author Tong-Xia Xia.

The original article has been updated.

Statements

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Summary

Keywords

cost-effectiveness analysis, advanced hepatocellular carcinoma, cabozantinib, atezolizumab, sorafenib

Citation

Zhu Y, He C, Cao S-C, Li H-J, Cai R-X, Bai Z-J and Xia T-X (2025) Correction: Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma. Front. Pharmacol. 16:1735585. doi: 10.3389/fphar.2025.1735585

Received

30 October 2025

Accepted

31 October 2025

Published

13 November 2025

Approved by

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Volume

16 - 2025

Updates

Copyright

*Correspondence: Tong-Xia Xia,

†These authors have contributed equally to this work and share first authorship

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics